Evidence map›Paper›PMID 41408357›Full record

ArticleImplementation science communications2025

Scaling up point-of-care hepatitis C testing in Canada: protocol for a multilevel implementation science study of clinical processes, barriers, facilitators and implementation strategies (SCALE-POCT study).

Meagan Mooney, Charlene Weight, Mia J Biondi, Jason Grebely, Nadine Kronfli, Tamara Barnett, Julie Bruneau, Kate Dunn, Daniel N Elakpa, Cole Etherington and 5 more

Erratum issued Registry-linked trialAbstract read
In one paragraph

Article in Implementation science communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07095192 (Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07095192 recruitingnot on this map

Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada: A Multilevel Implementation Science Study of Clinical Processes, Barriers, Facilitators and Implementation Strategies

Typeobservational_patient_registrySponsorMcGill UniversityRan2025 to 2028Enrolled300ConditionsHCV, HEPATITIS C VIRUS CHRONIC INFECTIONArmsPreimplementation of HCV Point of care testing
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Meagan MooneyIngram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, 680 Rue Sherbrooke O #1800, Montréal, QC, H3A 2M7, Canada.
Charlene WeightIngram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, 680 Rue Sherbrooke O #1800, Montréal, QC, H3A 2M7, Canada.
Mia J BiondiViral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease, Toronto, ON, Canada.
Jason GrebelyKirby Institute, University of New South Wales, Level 6, Wallace Wurth Building High Street, Sydney, 2052, Australia.
Nadine KronfliCentre for Outcomes Research and Evaluation, Research Institute of the McGill University Health Centre, 5252 de Maisonneuve Boulevard W., Montreal, QC, H4A 3S9, Canada.
Tamara BarnettSchool of Nursing, York University, 99 Ian Macdonald Blvd, Toronto, ON, M3J 1P3, Canada.
Julie BruneauCentre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 Saint-Denis Street, Montréal, QC, H2X 0A9, Canada.
Kate DunnViral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease, Toronto, ON, Canada.
Daniel N ElakpaIngram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, 680 Rue Sherbrooke O #1800, Montréal, QC, H3A 2M7, Canada.
Cole EtheringtonCentre for Implementation Research, Methodological and Implementation Research Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, K1H 8L6, Canada.
Christina GreenawayCentre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, CIUSSS West-Central Montreal, 3755 Chem. de La Côte-Sainte-Catherine, Montréal, QC, H3T 1E2, Canada.
Valérie Martel-LaferrièreCentre de Recherche du Centre Hospitalier de l'Université de Montréal, 900 Saint-Denis Street, Montréal, QC, H2X 0A9, Canada.
Andrew MendlowitzViral Hepatitis Care Network (VIRCAN), Toronto Centre for Liver Disease, Toronto, ON, Canada.
Natalie TaylorSchool of Population Health, UNSW Sydney, Samuels Building, Samuel Terry Ave, Kensington, NSW, F252052, Australia.
Guillaume FontaineIngram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, 680 Rue Sherbrooke O #1800, Montréal, QC, H3A 2M7, Canada. guil.fontaine@mcgill.ca.ORCID http://orcid.org/0000-0002-7806-814X

Funding

Institute of Health Services and Policy Research PJT-517467
6 · The paper itself

Abstract

backgroundAs the result of systemic and structural barriers, hepatitis C virus (HCV) continues to disproportionately affect people who inject drugs, those in prison, Indigenous peoples, immigrants from HCV-endemic countries, and gay, bisexual and other men who have sex with men in Canada. Point-of-care antibody and RNA testing improve access to HCV testing and enable single-visit diagnosis and treatment initiation, yet robust, context-specific strategies are needed to scale these technologies nationally. This protocol describes the SCALE-POCT study, which aims to: (i) map current HCV care pathways and future point-of-care workflows across community and carceral settings; (ii) identify multilevel barriers and facilitators to the adoption and sustainment of point-of-care HCV testing and treatment; (iii) co-design and operationalise theory-informed implementation strategies, protocols, and materials; and (iv) evaluate the acceptability, feasibility, and economic impacts of the co-designed strategies.

methodsGuided by Implementation Mapping and a health equity lens, the study will enroll 20 to 25 sites, including needle and syringe programs, overdose prevention programs, drug treatment clinics, outreach services, community health centers, Indigenous health organizations, and provincial prisons in British Columbia, Ontario, and Québec. Phase 1 will use process mapping focus groups, supplemented by aggregated HCV care cascade indicators, to document site-specific workflows and pinpoint bottlenecks. Phase 2 will employ semi-structured interviews guided by the Consolidated Framework for Implementation Research (CFIR), Kingdon's Multiple Streams Framework, and the Theoretical Domains Framework to characterize barriers and enablers at the outer setting, inner setting, intervention, individual, and process levels. Triangulated heat-mapping will enable cross-site comparisons. Phase 3 will link these determinants to implementation strategies using the Expert Recommendations for Implementing Change (ERIC) compilation and CFIR-ERIC Matching Tool. User-centered co-design workshops will then refine each strategy's actor, action, target, temporality, and dose, while also developing standard operating procedures, training modules, and quality assurance tools. Phase 4 will apply a mixed-methods evaluation of the implementation strategies developed, using validated instruments to quantify acceptability, appropriateness, and feasibility; feedback sessions to qualitatively assess contextual fit; and time-driven activity-based costing to estimate implementation resource requirements over pre-implementation, implementation, and sustainment periods. DISCUSSION: SCALE-POCT will deliver a rigorously co-designed implementation package, establishing the operational blueprint for large-scale, pragmatic implementation trials of point-of-care testing. It will support national HCV elimination targets while offering a transferable model for other sexually transmitted and blood-borne infections.

trial registrationThis study is registered at ClinicalTrials.gov, NCT07095192.

Indexed as

Hepatitis C virusImplementation scienceLinkage to carePoint-of-care testingTreatment

Identifiers

PMID41408357
PMCPMC12821820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.